|
WO2014059111A2
|
|
Method for increasing the oral bioavailability of a metabotropic glutamate 2/3 receptor antagonist
|
|
WO2013062680A1
|
|
Novel compounds and compositions thereof for treating nervous system disorders
|
|
WO2012170599A1
|
|
Neurogenesis by muscarinic receptor modulation
|
|
AU2010257456A1
|
|
5 HT receptor mediated neurogensis
|
|
CA2726300A1
|
|
5 ht receptor mediated neurogenesis
|
|
US2011269717A1
|
|
Neurogenesis by modulating angiotensin
|
|
US2011046090A1
|
|
Modulation of neurogenesis with gaba agents and gaba analogs
|
|
US2010216805A1
|
|
Modulation of neurogenesis using d-cycloserine combinations
|
|
US2010184806A1
|
|
Modulation of neurogenesis by ppar agents
|
|
US2010216734A1
|
|
Modulation of neurogenesis by nootropic agents
|
|
US2010009983A1
|
|
5 ht receptor mediated neurogenesis
|
|
US2009197823A1
|
|
Aliskiren modulation of neurogenesis
|
|
WO2009123877A1
|
|
A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
|
|
US2008188457A1
|
|
Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
|
|
AU2008204800A1
|
|
Modulation of neurogenesis with use of modafinil
|
|
CA2664421A1
|
|
Hmg coa reductase mediated modulation of neurogenesis
|
|
AU2007292848A1
|
|
Combinations containing a 4-acylaminopyridine derivative
|
|
CN101563083A
|
|
Combinations containing a 4-acylaminopyridine derivative
|
|
EP2377531A2
|
|
Neurogenesis by modulating angiotensin
|
|
US2008167291A1
|
|
Neurogenesis by modulating angiotensin
|
